Analysts' ratings for Capricor Therapeutics (NASDAQ:CAPR) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $27.83, a high estimate of $40.00, and a low estimate of $8.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.45%.
Understanding Analyst Ratings: A Comprehensive Breakdown
In examining...
Login or create a forever free account to read this news
Sign up/Log in